C&EN Whitepaper
Transforming Drug Development with Nanoparticle Engineering
Brought to you by Nanoform

Poor bioavailability and solubility are leading causes of drug development failure. This white paper delves into current technological innovations in nanoparticle engineering that aim to increase the number of drugs reaching the market by improving these properties. In particular, Nanoform’s Controlled Expansion of Supercritical Solutions (CESS®) nanoparticle engineering technology is explored as a technique that can uniformly shrink down the size of API particles in a sustainable and controlled process.

The white paper goes on to discuss the potential advantages the technology could bring to patients at all stages of life, including by facilitating novel drug delivery routes, increasing the number of drugs that succeed in clinical trials and reducing both dosage and side effects. Additionally, this white paper features a Nanoform case study on the use of CESS® to enhance the pharmacokinetic properties of piroxicam, a popular anti-inflammatory drug, and concludes with a focus on future expectations for the technology in the field.
Key Objectives:

  • Discover the connection between the poor bioavailability and solubility of new drug candidates and the high failure rates in drug development.
  • Learn more about the power of the latest nanoparticle engineering innovations as a method to reduce the size of drug particles

Brought to you by:
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) via email, in accordance with the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy